glp 1 microneedle patches Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Technology for Sustained Weekly Efficacy smgt-glp-1 nano microneedle patch -

K.AmeyawG

Nat Rev Drug Discov 10: 453471

(2016) 11:e0151736

Compliance with Key Standards Compliance with USP 1079, URAC 5.0, and ACHC standards is essential for GLP-1 medication safety

doi: 10.1007/s00125-011-2446-4 6 ArmstrongMJHullDGuoKBartonDHazlehurstJMGathercoleLLet al

The concerns about the adverse effects of non-noble varieties, produced by their undesirable composition of kavalactones and high concentrations of potentially harmful compounds (flavokavains, which are not present in any significant concentration in the noble varieties), have led to legislation prohibiting exports from countries such as Vanuatu